Bispecific antibody · Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 (CD3E) · developed by MacroGenics
MGD024 is a DART bispecific antibody-like protein that binds CD123, the interleukin-3 receptor alpha chain, on cancer cells and CD3 on T cells. By crosslinking the two, it activates T cells and drives cytotoxic T-lymphocyte killing of CD123-expressing cells. It is studied in hematologic malignancies including acute myeloid leukemia, myelodysplastic syndromes and Hodgkin lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05362773 | Phase 1 | Leukemia, Acute Myeloid | Active not recruiting | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Blastic Plasmacytoid Dendritic Cell NeoplasmChronic Myeloid LeukemiaClassical Hodgkin LymphomaLeukemia, Acute MyeloidLeukemia, B-cellLeukemia, Hairy CellMastocytosis, Aggressive SystemicMyelodysplastic Syndromes
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →